Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Disulfide cross-links in intestinal mucin polymers, primarily involving the MUC2 glycoprotein, are the fundamental structural elements that allow for the formation of the protective mucus gel in the gut. These covalent bonds form between the cysteine-rich D-domains at the amino- and carboxy-termini of mucin monomers, creating a massive, net-like polymer matrix that provides a physical barrier against pathogens and toxins while lubricating the intestinal wall (Johansson et al., 2011, Nature Reviews Gastroenterology & Hepatology). In healthy states, these cross-links maintain the integrity of the inner 'striated' mucus layer, which is largely impermeable to bacteria. In certain pathological conditions, such as cystic fibrosis or distal intestinal obstruction syndrome (DIOS), the mucus becomes excessively dehydrated and hyper-viscous due to altered cross-linking or concentration, leading to blockages. Conversely, in ulcerative colitis, the mucus layer is often thinned or compromised, potentially due to impaired polymer assembly or excessive degradation. Therapeutic targeting of these disulfide bonds typically involves mucolytic agents like N-acetylcysteine, which act as reducing agents to break the disulfide bridges, thereby liquefying the mucus and facilitating its clearance or penetration by other drugs (Hansson, 2012, Journal of Internal Medicine).
Reduction of covalent disulfide bonds between mucin monomers into free thiol groups, which breaks down the large polymer network into smaller subunits to decrease mucus viscosity.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Disulfide cross-links in intestinal mucin polymers (MUC2 disulfide bonds).